{"id":67437,"date":"2026-06-05T14:06:36","date_gmt":"2026-06-05T06:06:36","guid":{"rendered":"https:\/\/flcube.com\/?p=67437"},"modified":"2026-06-05T14:06:37","modified_gmt":"2026-06-05T06:06:37","slug":"ssy-group-secures-global-rights-to-pediatric-antispasmodic-and-copd-drugs-from-xinzheng-heying-full-ip-transfer-in-category-2-2-and-2-3-assets","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67437","title":{"rendered":"SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying \u2013 Full IP Transfer in Category 2.2 and 2.3 Assets"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>SSY Group Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/2005:HKG\">HKG: 2005<\/a>) announced it has signed a <strong>letter of intent<\/strong> with fellow Chinese pharmaceutical company <strong>Anhui Xinzheng Heying Pharmaceutical Technology Co., Ltd.<\/strong>, securing global exclusive rights to two late-stage development assets: a <strong>Category 2.2 antispasmodic drug for pediatric use<\/strong> and a <strong>Category 2.3 drug for chronic obstructive pulmonary disease (COPD)<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-transaction-framework\" class=\"wp-block-heading\">Transaction Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>SSY Group Limited (HKG: 2005)<\/td><\/tr><tr><td><strong>Developer<\/strong><\/td><td>Anhui Xinzheng Heying Pharmaceutical Technology Co., Ltd.<\/td><\/tr><tr><td><strong>Agreement Status<\/strong><\/td><td>Letter of Intent signed (final contract pending)<\/td><\/tr><tr><td><strong>Assets Acquired<\/strong><\/td><td>Category 2.2 pediatric antispasmodic drug<br>Category 2.3 COPD therapeutic<\/td><\/tr><tr><td><strong>Transfer Scope<\/strong><\/td><td>Complete technology transfer including all research data, patents, regulatory submissions, and global commercial rights<\/td><\/tr><tr><td><strong>Ownership Structure<\/strong><\/td><td>Upon final contract execution: SSY Group holds 100% IP, MAH rights, and commercial interests<\/td><\/tr><tr><td><strong>Developer Retention<\/strong><\/td><td>Authorship rights (if applicable) and milestone payment eligibility<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-asset-profile-amp-development-status\" class=\"wp-block-heading\">Asset Profile &amp; Development Status<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Pediatric Antispasmodic (Category 2.2):<\/strong><\/li>\n\n\n\n<li><strong>Indication:<\/strong> Pediatric spasticity disorders<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Advanced pharmaceutical and non-clinical research completed<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Category 2.2 classification indicates improved new drug with enhanced safety\/efficacy profile<\/li>\n\n\n\n<li><strong>COPD Therapeutic (Category 2.3):<\/strong><\/li>\n\n\n\n<li><strong>Indication:<\/strong> Chronic obstructive pulmonary disease<\/li>\n\n\n\n<li><strong>Development Stage:<\/strong> Comprehensive research package including pharmaceutical, non-clinical, and regulatory submission data<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Category 2.3 classification represents new formulation or new indication of existing active ingredient<\/li>\n\n\n\n<li><strong>Intellectual Property:<\/strong> Complete patent portfolio including patent application rights transferred to SSY Group<\/li>\n\n\n\n<li><strong>Commercial Rights:<\/strong> <strong>Global exclusive<\/strong> marketing authorization and commercialization rights<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-rationale-amp-market-opportunity\" class=\"wp-block-heading\">Strategic Rationale &amp; Market Opportunity<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Therapeutic Area<\/th><th>Market Characteristics<\/th><\/tr><\/thead><tbody><tr><td><strong>Pediatric Antispasmodics<\/strong><\/td><td>Limited treatment options for pediatric spasticity<br>High unmet medical need in cerebral palsy and other neurological conditions<br>Premium pricing supported by orphan-like market dynamics<\/td><\/tr><tr><td><strong>COPD Market<\/strong><\/td><td>Affects over 100 million people in China alone<br>Chronic condition requiring long-term management<br>Established reimbursement pathways and large patient population<\/td><\/tr><tr><td><strong>China Pharmaceutical Categories<\/strong><\/td><td><strong>Category 2.2:<\/strong> Improved new drugs with clinical advantages<br><strong>Category 2.3:<\/strong> New formulations\/new indications with expedited review pathways<br>Both categories eligible for priority review and premium pricing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-transaction-structure-amp-financial-implications\" class=\"wp-block-heading\">Transaction Structure &amp; Financial Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Payment Component<\/th><th>Recipient<\/th><th>Strategic Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Initial Payment<\/strong><\/td><td>Xinzheng Heying<\/td><td>Trigger for full IP and MAH rights transfer to SSY Group<\/td><\/tr><tr><td><strong>Milestone Payments<\/strong><\/td><td>Xinzheng Heying<\/td><td>Performance-based payments tied to development and commercial achievements<\/td><\/tr><tr><td><strong>IP Ownership<\/strong><\/td><td>SSY Group (100%)<\/td><td>Complete control over global development and commercialization strategy<\/td><\/tr><tr><td><strong>MAH Rights<\/strong><\/td><td>SSY Group (exclusive)<\/td><td>Direct regulatory relationship with NMPA and international agencies<\/td><\/tr><tr><td><strong>Commercial Interests<\/strong><\/td><td>SSY Group (sole owner)<\/td><td>Full revenue capture from global sales without royalty obligations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-competitive-advantages-for-ssy-group\" class=\"wp-block-heading\">Competitive Advantages for SSY Group<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Portfolio Diversification:<\/strong> Expands beyond existing business into high-value specialty pharmaceuticals<\/li>\n\n\n\n<li><strong>Development Efficiency:<\/strong> Acquires near-complete development packages, significantly de-risking late-stage development<\/li>\n\n\n\n<li><strong>Regulatory Strategy:<\/strong> Category 2.2 and 2.3 classifications support expedited approval pathways in China<\/li>\n\n\n\n<li><strong>Global Platform:<\/strong> Secures worldwide rights enabling international expansion beyond Chinese market<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Combined peak annual sales projected at $150-250 million globally across both indications<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding transaction completion, regulatory pathways, and commercial expectations. Actual results may differ due to risks including final contract execution, regulatory decisions, and market dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060402536_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026060402536_c.\"><\/object><a id=\"wp-block-file--media-b997c231-f4a1-4f11-8238-1774001b4c2f\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060402536_c.pdf\">2026060402536_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2026060402536_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-b997c231-f4a1-4f11-8238-1774001b4c2f\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SSY Group Limited (HKG: 2005) announced it has signed a letter of intent with fellow&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[2479,2480,4778],"class_list":["post-67437","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-hkg-2005","tag-ssy-group","tag-xinzheng-heying-pharmaceutical-technology"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying \u2013 Full IP Transfer in Category 2.2 and 2.3 Assets - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"SSY Group Limited (HKG: 2005) announced it has signed a letter of intent with fellow Chinese pharmaceutical company Anhui Xinzheng Heying Pharmaceutical Technology Co., Ltd., securing global exclusive rights to two late-stage development assets: a Category 2.2 antispasmodic drug for pediatric use and a Category 2.3 drug for chronic obstructive pulmonary disease (COPD).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67437\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying \u2013 Full IP Transfer in Category 2.2 and 2.3 Assets\" \/>\n<meta property=\"og:description\" content=\"SSY Group Limited (HKG: 2005) announced it has signed a letter of intent with fellow Chinese pharmaceutical company Anhui Xinzheng Heying Pharmaceutical Technology Co., Ltd., securing global exclusive rights to two late-stage development assets: a Category 2.2 antispasmodic drug for pediatric use and a Category 2.3 drug for chronic obstructive pulmonary disease (COPD).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67437\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-05T06:06:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-05T06:06:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67437#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67437\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying \u2013 Full IP Transfer in Category 2.2 and 2.3 Assets\",\"datePublished\":\"2026-06-05T06:06:36+00:00\",\"dateModified\":\"2026-06-05T06:06:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67437\"},\"wordCount\":491,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"HKG: 2005\",\"SSY Group\",\"Xinzheng Heying Pharmaceutical Technology\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67437#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67437\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67437\",\"name\":\"SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying \u2013 Full IP Transfer in Category 2.2 and 2.3 Assets - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-05T06:06:36+00:00\",\"dateModified\":\"2026-06-05T06:06:37+00:00\",\"description\":\"SSY Group Limited (HKG: 2005) announced it has signed a letter of intent with fellow Chinese pharmaceutical company Anhui Xinzheng Heying Pharmaceutical Technology Co., Ltd., securing global exclusive rights to two late-stage development assets: a Category 2.2 antispasmodic drug for pediatric use and a Category 2.3 drug for chronic obstructive pulmonary disease (COPD).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67437#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67437\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67437#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying \u2013 Full IP Transfer in Category 2.2 and 2.3 Assets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying \u2013 Full IP Transfer in Category 2.2 and 2.3 Assets - Insight, China&#039;s Pharmaceutical Industry","description":"SSY Group Limited (HKG: 2005) announced it has signed a letter of intent with fellow Chinese pharmaceutical company Anhui Xinzheng Heying Pharmaceutical Technology Co., Ltd., securing global exclusive rights to two late-stage development assets: a Category 2.2 antispasmodic drug for pediatric use and a Category 2.3 drug for chronic obstructive pulmonary disease (COPD).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67437","og_locale":"en_US","og_type":"article","og_title":"SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying \u2013 Full IP Transfer in Category 2.2 and 2.3 Assets","og_description":"SSY Group Limited (HKG: 2005) announced it has signed a letter of intent with fellow Chinese pharmaceutical company Anhui Xinzheng Heying Pharmaceutical Technology Co., Ltd., securing global exclusive rights to two late-stage development assets: a Category 2.2 antispasmodic drug for pediatric use and a Category 2.3 drug for chronic obstructive pulmonary disease (COPD).","og_url":"https:\/\/flcube.com\/?p=67437","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-05T06:06:36+00:00","article_modified_time":"2026-06-05T06:06:37+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67437#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67437"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying \u2013 Full IP Transfer in Category 2.2 and 2.3 Assets","datePublished":"2026-06-05T06:06:36+00:00","dateModified":"2026-06-05T06:06:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67437"},"wordCount":491,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["HKG: 2005","SSY Group","Xinzheng Heying Pharmaceutical Technology"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67437#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67437","url":"https:\/\/flcube.com\/?p=67437","name":"SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying \u2013 Full IP Transfer in Category 2.2 and 2.3 Assets - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-05T06:06:36+00:00","dateModified":"2026-06-05T06:06:37+00:00","description":"SSY Group Limited (HKG: 2005) announced it has signed a letter of intent with fellow Chinese pharmaceutical company Anhui Xinzheng Heying Pharmaceutical Technology Co., Ltd., securing global exclusive rights to two late-stage development assets: a Category 2.2 antispasmodic drug for pediatric use and a Category 2.3 drug for chronic obstructive pulmonary disease (COPD).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67437#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67437"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67437#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying \u2013 Full IP Transfer in Category 2.2 and 2.3 Assets"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67437"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67437\/revisions"}],"predecessor-version":[{"id":67440,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67437\/revisions\/67440"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}